Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
nanobiotix第三季度更新重點：第三階段頭頸癌試驗轉移到Janssen，Curadigm平台擴張；現金儲備5320萬歐元
- Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission
- Added expert industry leaders to Supervisory Board, further strengthening support for the Company's long-term growth strategy
- NBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectively
- Update on expansion of product portfolio to include disruptive nanotherapeutic platform Curadigm expected 4Q 2024
- €53.2 million in cash and cash equivalents as of September 30, 2024 with cash runway into 4Q 2025
- 將NANORAY-312頭頸癌全球三期研究的美國贊助轉移，這是爲潛在NBTXR3監管提交做準備的關鍵一步
- 向監事會增加專業行業領袖，進一步加強對公司長期增長策略的支持
- 預計NBTXR3項目更新包括胰腺癌研究和肺癌研究，預計分別在2024年第4季度和2025年上半年由MD Anderson進行
- 預計產品組合擴展包括顛覆性納米治療平台Curadigm，預計在2024年第4季度推出
- 截至2024年9月30日，現金及現金等價物爲€5320萬，現金儲備可支持至2025年第4季度
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間